Video
Bleeding risk in patients using Botox treatments and blood thinners
Author(s):
“The notable feature was that the bleeding risk is very small. In our particular group, it was less than 1%,” says Jai Seth, MD.
Video Player is loading.
In this video, Jai Seth, MD, discusses the findings of the Neurourology and Urodynamics study, “Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy.” Seth is a consultant urological surgeon at St. George’s University hospital, London, UK.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Justin Dubin, MD, on leveraging digital tools to improve patient buy-in
Betty Wang, MD, and Laura Bukavina, MD, MPH, MSc, discuss ctDNA's role in NMIBC treatment decisions
Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation system
Mina Fam, MD, on managing expectations around testosterone replacement therapy
Justin Dubin, MD, on the role for AI in patient education
Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
TMT for bladder cancer: Balancing cost and quality of life
Anne Schuckman, MD, outlines current challenges in NMIBC care
Justin Dubin, MD, on the use of AI in the male infertility space
Bilal Chughtai, MD, discusses pivotal trial of the Butterfly device for BPH
Related Content
